MOSCOW (Sputnik) – India’s Drug Controller General (DCGI) has issued permission for Dr. Reddy’s Laboratories, specialised in pharmacy, to import Russia’s Sputnik V vaccine against COVID-19 to India for emergency use, the company said on Tuesday.
On Monday, India became the 60th country to authorise use of Sputnik V. The Russian vaccine, developed by Moscow-based Gamaleya National Center, became the third vaccine registered in India along with the locally-produced variant of AstraZeneca vaccine branded Covieshield, and India’s Covaxin.
GV Prasad, the company’s co-chairman and managing director, said that the enterprise was “very pleased to obtain the emergency use authorisation for Sputnik V in India” given that vaccines are the best instrument to contain the rising number of COVID-19 cases.
He added that this step “will enable us to contribute to our nation’s effort of vaccinating a significant proportion of our population.”
In September 2020, Dr. Reddy’s Laboratories signed an agreement with the Russian Direct Investment Fund (RDIF), which promotes Sputnik V, to conduct clinical tests of the vaccine in India. In addition, RDIF has contracts with five Indian producers — Hetero Biopharma, Gland Pharma, Stelis Biopharma, Virchow Biotech, and Panacea Biotec — on the vaccine’s manufacturing.
Sourse: sputniknews.com
0.00 (0%) 0 votes
